Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings

Bioorg Med Chem Lett. 2009 Feb 15;19(4):1105-9. doi: 10.1016/j.bmcl.2008.12.111. Epub 2009 Jan 8.

Abstract

Extensive SAR studies of the P3 capping group led to the discovery of a series of potent inhibitors with sultam and cyclic sulfonyl urea moieties as the P3 capping. The bicyclic thiophene-sultam or phenyl-sultam cappings were selected for further SAR development. Modification at the P3 side chain determined that the tert-butyl group was the best choice at that position. Optimization of P1 residue significantly improved potency and selectivity. The combination of optimal moieties at all positions led to the discovery of compound 33. This compound had the best overall profile in potency and PK profile: excellent K(i)(*) of 5.3 nM and activity in replicon (EC(90)) of 80 nM, extremely high selectivity of 6100, and a good rat PO AUC of 1.43 microMh.

MeSH terms

  • Administration, Oral
  • Animals
  • Antiviral Agents / chemical synthesis*
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology*
  • Combinatorial Chemistry Techniques
  • Drug Design
  • Hepacivirus / drug effects*
  • Molecular Structure
  • Protease Inhibitors / chemical synthesis*
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / pharmacology*
  • Rats
  • Structure-Activity Relationship
  • Sulfonylurea Compounds / chemical synthesis*
  • Sulfonylurea Compounds / chemistry
  • Sulfonylurea Compounds / pharmacology*
  • Thiazines / chemistry
  • Viral Nonstructural Proteins / drug effects*

Substances

  • Antiviral Agents
  • NS3 protein, hepatitis C virus
  • Protease Inhibitors
  • Sulfonylurea Compounds
  • Thiazines
  • Viral Nonstructural Proteins
  • sulthiame